SG11202103070VA - Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases - Google Patents
Donecopride as neuroprotective agent in the treatment of neurodegenerative diseasesInfo
- Publication number
- SG11202103070VA SG11202103070VA SG11202103070VA SG11202103070VA SG11202103070VA SG 11202103070V A SG11202103070V A SG 11202103070VA SG 11202103070V A SG11202103070V A SG 11202103070VA SG 11202103070V A SG11202103070V A SG 11202103070VA SG 11202103070V A SG11202103070V A SG 11202103070VA
- Authority
- SG
- Singapore
- Prior art keywords
- donecopride
- treatment
- neurodegenerative diseases
- neuroprotective agent
- neuroprotective
- Prior art date
Links
- FTRZTHFGTILUPE-UHFFFAOYSA-N 1-(4-amino-5-chloro-2-methoxyphenyl)-3-[1-(cyclohexylmethyl)piperidin-4-yl]propan-1-one Chemical compound COC1=CC(N)=C(Cl)C=C1C(=O)CCC1CCN(CC2CCCCC2)CC1 FTRZTHFGTILUPE-UHFFFAOYSA-N 0.000 title 1
- 230000004770 neurodegeneration Effects 0.000 title 1
- 208000015122 neurodegenerative disease Diseases 0.000 title 1
- 239000004090 neuroprotective agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18306280.1A EP3628660A1 (en) | 2018-09-28 | 2018-09-28 | Donecopride and flucopride as neuroprotective agents in the treatment of neurodegenerative diseases |
| PCT/EP2019/076229 WO2020065028A1 (en) | 2018-09-28 | 2019-09-27 | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103070VA true SG11202103070VA (en) | 2021-04-29 |
Family
ID=63798921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103070VA SG11202103070VA (en) | 2018-09-28 | 2019-09-27 | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20220031680A1 (https=) |
| EP (2) | EP3628660A1 (https=) |
| JP (1) | JP2022511366A (https=) |
| KR (1) | KR20210098429A (https=) |
| CN (1) | CN113195452A (https=) |
| AU (1) | AU2019346024B2 (https=) |
| BR (1) | BR112021005952A2 (https=) |
| CA (1) | CA3115342A1 (https=) |
| SG (1) | SG11202103070VA (https=) |
| WO (1) | WO2020065028A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR3166060A1 (fr) | 2024-09-12 | 2026-03-13 | Université De Caen Normandie | Composition pharmaceutique formulée pour être administrée par voie intranasale et utilisable pour le traitement d’une maladie neurodégénérative |
| FR3166146A1 (fr) | 2024-09-12 | 2026-03-13 | Université De Caen Normandie | Sel de fumarate de 1-(4-amino-5-chloro-2-méthoxyphényl)-3-[1-(cycloheptylméthyl)-4-pipéridinyl]propan-1-one –Composition pharmaceutique et utilisation associées |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407966B2 (en) * | 2004-10-07 | 2008-08-05 | Epix Delaware, Inc. | Thienopyridinone compounds and methods of treatment |
| FR2904113A1 (fr) | 2006-07-21 | 2008-01-25 | Exonhit Therapeutics S A Sa | Procedes et outils pour la therapie de pathologies neurodegeneratives |
| CN102355902A (zh) * | 2009-01-24 | 2012-02-15 | 植物药物公共有限公司 | 神经营养因子介导的病症的处理 |
| FR3006686A1 (fr) * | 2013-06-05 | 2014-12-12 | Univ Caen | Composes inhibiteurs de l'acetylcholinesterase et agonistes des recepteurs serotoninergiques 5ht4, a effet promnesiant, leurs procedes de preparation et compositions pharmaceutiques les contenant |
| KR101824154B1 (ko) * | 2013-12-16 | 2018-03-14 | 수벤 라이프 사이언시스 리미티드 | 5-ｈｔ４ 수용체 작용제로서 인다졸 화합물 |
-
2018
- 2018-09-28 EP EP18306280.1A patent/EP3628660A1/en not_active Withdrawn
-
2019
- 2019-09-27 US US17/280,217 patent/US20220031680A1/en not_active Abandoned
- 2019-09-27 BR BR112021005952-0A patent/BR112021005952A2/pt unknown
- 2019-09-27 KR KR1020217009149A patent/KR20210098429A/ko not_active Ceased
- 2019-09-27 EP EP19783459.1A patent/EP3856716A1/en active Pending
- 2019-09-27 SG SG11202103070VA patent/SG11202103070VA/en unknown
- 2019-09-27 CN CN201980063618.3A patent/CN113195452A/zh active Pending
- 2019-09-27 CA CA3115342A patent/CA3115342A1/en active Pending
- 2019-09-27 JP JP2021517453A patent/JP2022511366A/ja active Pending
- 2019-09-27 AU AU2019346024A patent/AU2019346024B2/en not_active Ceased
- 2019-09-27 WO PCT/EP2019/076229 patent/WO2020065028A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020065028A1 (en) | 2020-04-02 |
| AU2019346024B2 (en) | 2024-07-18 |
| JP2022511366A (ja) | 2022-01-31 |
| EP3628660A1 (en) | 2020-04-01 |
| AU2019346024A1 (en) | 2021-04-29 |
| CA3115342A1 (en) | 2020-04-02 |
| BR112021005952A2 (pt) | 2021-06-29 |
| KR20210098429A (ko) | 2021-08-10 |
| US20220031680A1 (en) | 2022-02-03 |
| CN113195452A (zh) | 2021-07-30 |
| EP3856716A1 (en) | 2021-08-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202004025B (en) | Novel compounds and pharmaceutical compositions thereof for the treatment of diseases | |
| IL273959A (en) | Methods and preparations for the treatment of rare diseases | |
| ZA201908165B (en) | Compounds for the prevention and treatment of diseases and the use thereof | |
| PL3577135T3 (pl) | Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5 | |
| IL265902A (en) | Complex mixtures containing cannabinoids for the treatment of neurodegenerative diseases | |
| IL274578A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| EP3268007A4 (en) | Compositions and therapeutic methods for the treatment of complement-associated diseases | |
| IL281585B (en) | Selenogalactoside compounds for the prevention and treatment of galectin-related diseases and their use | |
| IL286767A (en) | Preparations and methods of their use for the treatment of neurodegenerative and mitochondrial diseases | |
| IL274588A (en) | Methods and preparations for improving lysosome function and treating neurodegenerative disease | |
| IL266486A (en) | Pharmaceutical preparations and methods for cancer treatment | |
| PL3508202T3 (pl) | Środek terapeutyczny i kompozycja do leczenia stwardnienia zanikowego bocznego | |
| IL275525A (en) | A pharmaceutical preparation for the treatment of cancer | |
| IL272495A (en) | Pharmaceutical compounds and preparations thereof for use in the treatment of leiftic diseases | |
| SG11202103070VA (en) | Donecopride as neuroprotective agent in the treatment of neurodegenerative diseases | |
| PL3352742T3 (pl) | Kompozycje zawierające triterpenoidy do leczenia choroby alzheimera i choroby parkinsona | |
| IL269121A (en) | Usl-311 for use in the treatment of cancer | |
| IL259383A (en) | A compound for use in the prevention and treatment of neurodegenerative diseases | |
| SMT202100070T1 (it) | Complesso e composizioni per il trattamento di affezioni oculari e cutanee | |
| PL3548006T3 (pl) | Kompozycja do stosowania w leczeniu zmian jelitowych | |
| EP3272349A4 (en) | Therapeutic and/or prophylactic agent for lewy body diseases | |
| GB201603510D0 (en) | Compositions for use in the treatment of neurological disease | |
| GB201718838D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| GB201712742D0 (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases | |
| HK40036525A (en) | Compounds and pharmaceutical compositions thereof for use in the treatment of fibrotic diseases |